Literature DB >> 17473308

Striking back at the activator: how IkappaB kinase terminates antigen receptor responses.

Michael Hinz1, Claus Scheidereit.   

Abstract

Antigen recognition by the T cell receptor (TCR) elicits several intracellular signaling cascades, one of which activates the transcription factor NF-kappaB through IkappaB kinases (IKK). NF-kappaB regulates lymphocyte differentiation, proliferation, and apoptosis; thus, tight temporal control of its activation is required to prevent harmful immune cell dysregulation. Although considerable insight into the IKK and NF-kappaB activation process has emerged, less is known about the temporal regulation and termination of immunoreceptor signaling. Two recent studies have revealed that the scaffold protein Bcl10--which, together with CARMA1 and Malt1, forms the TCR-induced IKK-activating CBM complex--is a negative feedback substrate for IKK. IKKbeta initially contributes to CBM formation--which is required for full IKK activation--and then, through carboxyl-terminal Bcl10 phosphorylation, disrupts this structure to terminate signaling. IKK triggers Bcl10 degradation by the ubiquitin-proteasome system through phosphorylation of Bcl10 at other sites. Thus, inactivation through negative feedback mechanisms is an intrinsic property of the TCR-induced NF-kappaB pathway.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17473308     DOI: 10.1126/stke.3842007pe19

Source DB:  PubMed          Journal:  Sci STKE        ISSN: 1525-8882


  2 in total

Review 1.  Crosstalk in NF-κB signaling pathways.

Authors:  Andrea Oeckinghaus; Matthew S Hayden; Sankar Ghosh
Journal:  Nat Immunol       Date:  2011-07-19       Impact factor: 25.606

2.  The Ca2+-dependent phosphatase calcineurin controls the formation of the Carma1-Bcl10-Malt1 complex during T cell receptor-induced NF-kappaB activation.

Authors:  Lysann Palkowitsch; Uta Marienfeld; Cornelia Brunner; Andrea Eitelhuber; Daniel Krappmann; Ralf B Marienfeld
Journal:  J Biol Chem       Date:  2011-01-03       Impact factor: 5.157

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.